Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP4 | P49662 | 1/20 | 0.32 |
| ▸ | CASP5 | P51878 | 1/20 | 0.32 |
| ▸ | INMT | O95050 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567898 | 0.85 | HRH1 (0.39) | USP2SMN1; SMN2TDP1HRH1CASP1 | |
| SCHEMBL368445 | 0.60 | HTR2C (0.47) | USP2SMN1; SMN2TDP1HRH1CASP1 | |
| SCHEMBL5634363 | 0.58 | USP2 (0.36) | USP2SMN1; SMN2TDP1HRH1HTR2C | |
| SCHEMBL13460691 | 0.58 | USP2 (0.45) | USP2SMN1; SMN2TDP1HRH1INMT | |
| SCHEMBL778188 | 0.58 | SMN1; SMN2 (1.00) | USP2SMN1; SMN2TDP1HRH1CASP1 | |
| SCHEMBL76532 | 0.58 | — | — | |
| SCHEMBL3615 | 0.58 | — | — | |
| SCHEMBL1771063 | 0.58 | — | — | |
| SCHEMBL338532 | 0.57 | HTR2C (0.49) | USP2SMN1; SMN2TDP1HRH1CASP1 | |
| SCHEMBL16549762 | 0.55 | INMT (0.52) | USP2SMN1; SMN2TDP1HRH1INMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242639-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-02 | — | — | US | disclosed |
| WO-2004089901-A2 | PHOSPHOLIPASE C INHIBITORS FOR USE IN TREATING INFLAMMATORY DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242639-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | USP2 2306/4885SMN1; SMN2 3997/4885TDP1 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.